Skip to main content
ANTEROGEN CO., LTD. logo

ANTEROGEN CO., LTD. — Investor Relations & Filings

Ticker · 065660 ISIN · KR7065660003 KO Manufacturing
Open in API
Filings indexed 267 across all filing types
Latest filing 2021-03-03 AGM Information
Country KR South Korea
Listing KO 065660

About ANTEROGEN CO., LTD.

http://anterogen.com

ANTEROGEN CO., LTD. is a bio-venture company engaged in the research, development, and commercialization of cell therapy products and orphan drugs. The company specializes in utilizing adult stem cells, particularly adipose-derived mesenchymal stem cells, to create innovative treatments. Its key commercialized products include Cupistem®, an autologous stem cell therapy for Crohn's fistula, and Queencell®. Anterogen's research pipeline extends to applications for musculoskeletal diseases, spinal injuries, and cardiovascular conditions. The company also offers stem cell banking services.

Recent filings

Filing Released Lang Actions
주주총회소집공고
AGM Information Classification · 98% confidence The document is a formal 'Notice of Annual General Meeting' (주주총회소집공고) for Anterogen Co., Ltd. It contains the meeting agenda, details on voting procedures (including electronic voting), and management information such as director activities and financial statements (balance sheet, income statement) to be approved at the meeting. This is a standard proxy statement/notice of meeting document provided to shareholders to solicit votes and provide information for the upcoming AGM.
2021-03-03 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a short announcement regarding the scheduling and details of an Investor Relations (IR) meeting/presentation. It specifies the date, time, location, and purpose of the meeting. Since it is an announcement of an event rather than the presentation slides themselves, and it is under 5,000 characters, it falls under the category of a regulatory announcement regarding corporate events.
2021-03-02 Korean
투자판단관련주요경영사항(. 이영양성수포성표피박리증환자를 대상으로 ALL-ASC-SHEET의 유효성과 안전성을 평가하는 제 2상 임상시험 계획 승인(미국))
Regulatory Filings Classification · 95% confidence The document is a regulatory filing from a Korean company (Antrogen) regarding a material business event, specifically the approval of a Phase 2 clinical trial by the US FDA. This type of disclosure is a standard regulatory announcement for material corporate developments that do not fit into specific categories like financial reports or shareholder meetings. Therefore, it is classified as a general regulatory filing.
2021-02-17 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by Antrogen. It outlines the date, location, and agenda items (such as approval of financial statements, election of directors, and remuneration limits) for the upcoming Annual General Meeting. This type of document is a standard proxy solicitation or notice of meeting material provided to shareholders to inform them of the meeting and request their participation/votes.
2021-02-08 Korean
[기재정정]임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a regulatory filing from the Korean Financial Supervisory Service (DART system) titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This document details the share ownership and changes in holdings by an executive (Lee Tae-hee) of Antrogen Co., Ltd. This falls under the category of 'Director's Dealing' (DIRS), which covers reports of personal share transactions and ownership status by company directors and executives.
2021-02-05 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea (DART system) used when an individual or entity acquires a significant stake (typically 5% or more) in a company. This document details the shareholding status, changes in ownership, and the purpose of holding (management participation). It fits the definition of a 'Major Shareholding Notification' (MRQ).
2021-02-04 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.